|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Lipid Research, Vol. 50, S40-S45, April 2009
5-Lipoxygenase: mechanisms of regulation1
Department Medical Biochemistry and Biophysics, Division of Physiological Chemistry II, Karolinska Institutet, S-17177 Stockholm, Sweden 1 This paper is dedicated to Professor E. J. Corey in connection with his 80th birthday. Studies in our laboratory were supported by the Swedish Research Council (03X-217), Karolinska Institutet, and the European Union (LSHM-CT-2004-005033). Published, JLR Papers in Press, November 5, 2008.
2 To whom correspondence should be addressed. e-mail: olof.radmark{at}ki.se
5-Lipoxygenase (5-LO) catalyzes two steps in biosynthesis of leukotrienes (LTs), a group of lipid mediators of inflammation derived from arachidonic acid (AA). LT antagonists are used in treatment of asthma; more recently a potential role also in atherosclerosis has raised considerable interest. Furthermore, possible effects of 5-LO metabolites in relation to tumorigenesis have emerged. Thus, an understanding of the biochemistry of this lipoxygenase has potential implications for treatment of various diseases.
Supplementary key words arachidonic acid leukotriene inflammation
Related Webpages:
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||